Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

10 mars 2016 09h00 HE | Source: Trillium Therapeutics Inc.

Trillium Announces a $3.4 Million Government Co-Funded Translational Research Program

TORONTO, ONTARIO--(Marketwired - March 10, 2016) - Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TR) a clinical stage immuno-oncology company developing innovative therapies for the...
09 mars 2016 17h30 HE | Source: Trillium Therapeutics Inc.

Trillium Reports 2015 Financial and Operating Results

TORONTO, ONTARIO--(Marketwired - March 9, 2016) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR) a clinical stage immuno-oncology company developing innovative therapies for the...
08 mars 2016 07h00 HE | Source: Trillium Therapeutics Inc.

Trillium to Present at the Cowen and Company 36th Annual Health Care Conference

TORONTO, ONTARIO--(Marketwired - March 8, 2016) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR) a clinical stage immuno-oncology company developing innovative therapies for the...
03 févr. 2016 07h00 HE | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Doses First Patient With TTI-621, a Novel Immune Checkpoint Inhibitor Targeting CD47

TORONTO, ONTARIO--(Marketwired - Feb. 3, 2016) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR) a clinical stage immuno-oncology company developing innovative therapies for the...
27 janv. 2016 08h13 HE | Source: Trillium Therapeutics Inc.

Trillium Acquires Privately-Held Fluorinov Pharma Inc.

TORONTO, ONTARIO--(Marketwired - Jan. 27, 2016) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR) a clinical immuno-oncology company developing innovative therapies for the treatment of...
03 déc. 2015 07h00 HE | Source: Trillium Therapeutics Inc.

Trillium to Provide Update on CD47 Immune Checkpoint Inhibitor Program at the 2015 American Society of Hematology Annual Meeting

TORONTO, ONTARIO--(Marketwired - Dec. 3, 2015) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR) an immuno-oncology company developing innovative therapies for the treatment of cancer,...
30 sept. 2015 07h00 HE | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Provides Update on CD47 Program

TORONTO, ONTARIO--(Marketwired - Sept. 30, 2015) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR), an immuno-oncology company developing innovative therapies for the treatment of...
29 mai 2015 17h00 HE | Source: Trillium Therapeutics Inc.

Trillium Announces Voting Results From the Annual Meeting of Shareholders

TORONTO, May 29, 2015 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq:TRIL) (TSX:TR) an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the...
16 avr. 2015 08h45 HE | Source: Trillium Therapeutics Inc.

Trillium to Provide Update on CD47 Program at the 2015 American Association for Cancer Research Annual Meeting

TORONTO, April 16, 2015 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq:TRIL) (TSX:TR) an immuno-oncology company developing innovative therapies for the treatment of cancer, today...
07 avr. 2015 16h01 HE | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Announces Completion of Public Offering of Securities

TORONTO, April 7, 2015 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq:TRIL) (TSX:TR) an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced...

Page précédente